Vistagen therapeutics stock.

Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price. SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing ...VistaGen Therapeutics Inc. Watch Set a price target alert After Hours Last Updated: Nov 24, 2023 4:56 p.m. EST Delayed quote $ 3.5300 -0.06 -1.67% After Hours Volume: 4.3K Advanced Charting...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently …

VistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After hours: 07:55PM...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ...

Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the …

SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ...Maxim Group analyst Jason McCarthy maintained a Hold rating on VistaGen Therapeutics (VTGN – Research Report) yesterday.The company’s shares opened today at $0.15. McCarthy covers the ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...There are 137 funds or institutions reporting positions in VistaGen Therapeutics. This is a decrease of 34 owner (s) or 19.88% in the last quarter. Average portfolio weight of all funds dedicated ...

Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...

What are individual investors saying about Vistagen Therapeutics? View the latest VTGN social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat ...

The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. We ...Mar 22, 2023 · VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ... VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...

Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...Dec 1, 2023 · VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ... Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. 1.34. +0.02. +1.52%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...

What are individual investors saying about Vistagen Therapeutics? View the latest VTGN social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat ...Jul 18, 2023 · Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ...

Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage …Aug 7, 2023 · This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data. The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...7.32%. $1.48B. VTGN | Complete VistaGen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …

If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements. Investors. Mark McPartland. Senior Vice President, Investor Relations (650) 577-3606. [email protected]. Media. Nate Hitchings. …

Aug 13, 2014 · PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014.

Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the …Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Oct 28, 2022 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ... Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.VistaGen Therapeutics stock news, updates & related news. Find out why VistaGen Therapeutics's (VTGN) news sentiment is 12.96% more negative in relation to ...On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 – 15, 2023 at the Lotte New ...Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.Biotech Firm Pops 677% on Social Anxiety Spray Trial Success. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits ...The current Vistagen Therapeutics [ VTGN] share price is $3.38. The Score for VTGN is 29, which is 42% below its historic median score of 50, and infers higher risk than normal. VTGN is currently trading in the 20-30% percentile range relative to …Instagram:https://instagram. flrtexas home mortgage lenderschat gpt stocks to buyintl stock View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) … stock trading platform for day tradersetf that pays monthly dividend The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ... pomerantz llp 5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.